Drugs / Rozibafusp Alfa
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03156023 | Aug 2017 → Oct 2019 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02618967 | Mar 2016 → Sep 2018 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04058028 | Feb 2020 → Jul 2023 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rozibafusp Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03156023 ↗ |
| Known as | AMG 570 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02618967 ↗ |
| Known as | MEDI-0700 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650245 ↗ |
| Action | Inhibit | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL4650245 ↗1“Inducible T-cell costimulator inhibitor” CHEMBL4650245 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4650245 ↗ |
| Route | Subcutaneous | “7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.” NCT02618967 ↗ |
| Target | ICOS | “Inducible T-cell costimulator inhibitor” CHEMBL4650245 ↗ |
| Target | TNFSF13B | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL4650245 ↗ |